Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for DURECT Corporation (DRRX : NSDQ)
 
 • Company Description   
Durect Corp. is pioneering the treatment of chronic diseases and conditions by developing and commercializing pharmaceutical systems to deliver the right drug to the right place in the right amount at the right time. Its pharmaceutical systems combine engineering innovations and delivery technology from the medical device and drug delivery industries with its proprietary pharmaceutical and biotechnology drug formulations.

Number of Employees: 21

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.64 Daily Weekly Monthly
20 Day Moving Average: 38,063 shares
Shares Outstanding: 31.04 (millions)
Market Capitalization: $19.76 (millions)
Beta: 0.64
52 Week High: $1.74
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -0.52% -4.24%
12 Week -14.62% -28.18%
Year To Date -15.11% -20.50%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10240 BUBB ROAD
-
CUPERTINO,CA 95014
USA
ph: 408-777-1417
fax: 408-777-3577
svonderweid@lifesciadvisors.com http://www.durect.com
 
 • General Corporate Information   
Officers
James E. Brown - President; Chief Executive Officer and Director
Gail J. Maderis - Chairman of the Board and Director
Timothy M. Papp - Chief Financial Officer
Mohammad Azab - Director
Gail M. Farfel - Director

Peer Information
DURECT Corporation (GSAC)
DURECT Corporation (CASI)
DURECT Corporation (ALCD.)
DURECT Corporation (OMNN)
DURECT Corporation (CGPI.)
DURECT Corporation (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 266605500
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 31.04
Most Recent Split Date: 12.00 (0.10:1)
Beta: 0.64
Market Capitalization: $19.76 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.66 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.69
Price/Cash Flow: -
Price / Sales: 4.06
EPS Growth
vs. Year Ago Period: 48.00%
vs. Previous Quarter: -116.67%
Sales Growth
vs. Year Ago Period: -82.43%
vs. Previous Quarter: -29.14%
ROE
06/30/25 - -
03/31/25 - -267.36
12/31/24 - -292.84
ROA
06/30/25 - -
03/31/25 - -64.00
12/31/24 - -63.93
Current Ratio
06/30/25 - -
03/31/25 - 1.23
12/31/24 - 1.71
Quick Ratio
06/30/25 - -
03/31/25 - 1.22
12/31/24 - 1.70
Operating Margin
06/30/25 - -
03/31/25 - -284.48
12/31/24 - -271.87
Net Margin
06/30/25 - -
03/31/25 - -91.54
12/31/24 - -123.41
Pre-Tax Margin
06/30/25 - -
03/31/25 - -305.34
12/31/24 - -906.65
Book Value
06/30/25 - -
03/31/25 - 0.17
12/31/24 - 0.29
Inventory Turnover
06/30/25 - -
03/31/25 - 0.06
12/31/24 - 0.04
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©